Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARD | Q03181 | 8/20 | 0.52 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.45 |
| ▸ | GPR84 | Q9NQS5 | 7/20 | 0.45 |
| ▸ | PPARG | P37231 | 7/20 | 0.45 |
| ▸ | PPARA | Q07869 | 7/20 | 0.45 |
| ▸ | HDAC11 | Q96DB2 | 5/20 | 0.45 |
| ▸ | TSHR | P16473 | 5/20 | 0.45 |
| ▸ | PTPN1 | P18031 | 3/20 | 0.45 |
| ▸ | TLR2 | O60603 | 2/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.45 |
| ▸ | FABP4 | P15090 | 2/20 | 0.45 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.45 |
| ▸ | SLC22A8 | Q8TCC7 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | ESR1 | P03372 | 1/20 | 0.45 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.45 |
| ▸ | PDE4A | P27815 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4229202 | 0.98 | PPARD (0.50) | PPARDAKR1B1ALDH1A1GPR84PPARG | |
| SCHEMBL31494109 | 0.98 | PPARD (0.50) | PPARDAKR1B1ALDH1A1GPR84PPARG | |
| SCHEMBL21805452 | 0.98 | PPARD (0.50) | PPARDAKR1B1ALDH1A1GPR84PPARG | |
| SCHEMBL2383184 | 0.94 | PPARD (0.54) | PPARDAKR1B1ALDH1A1GPR84PPARG | |
| SCHEMBL28280048 | 0.91 | ALDH1A1 (0.46) | PPARDAKR1B1ALDH1A1GPR84PPARG | |
| SCHEMBL1276434 | 0.85 | PPARD (0.58) | PPARDAKR1B1ALDH1A1GPR84PPARG | |
| SCHEMBL29169497 | 0.84 | PPARD (0.52) | PPARDTSHR | |
| SCHEMBL28021210 | 0.83 | PPARD (0.56) | PPARDAKR1B1ALDH1A1GPR84PPARG | |
| SCHEMBL7268189 | 0.82 | PPARD (0.64) | PPARDTSHRTDP1 | |
| SCHEMBL29169496 | 0.82 | PPARD (0.50) | PPARDTSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140315790-A1 | AMINOTHIAZOLES AND THEIR USES | BUSHELL SIMON (US) | 2014-10-23 | — | — | US | disclosed |
| EP-2044101-B1 | AMINOTHIAZOLE DERIVATIVES AND THEIR USES AS ANTIBACTERIAL AGENTS | NOVARTIS AG (CH) | 2013-10-09 | — | — | EP | disclosed |
| EP-2401276-A1 | NITROGEN-CONTAINING FUSED HETEROCYCLIC COMPOUNDS AND THEIR USE AS BETA AMYLOID PRODUCTION INHIBITORS | Eisai R&D Management Co., Ltd. (JP) | 2012-01-04 | — | — | EP | disclosed |
| US-7851439-B2 | EFTU inhibitors or aminothiazoles and their uses | NOVARTIS AG (CH) | 2010-12-14 | — | — | US | disclosed |
| US-20100267757-A1 | AMINOTHIAZOLES AND THEIR USES | NOVARTIS AG (CH) | 2010-10-21 | — | — | US | disclosed |
| WO-2010098487-A1 | NITROGEN-CONTAINING FUSED HETEROCYCLIC COMPOUNDS AND THEIR USE AS BETA AMYLOID PRODUCTION INHIBITORS | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2010-09-02 | — | — | WO | disclosed |
| EP-2044101-A2 | AMINOTHIAZOLE DERIVATIVES AND THEIR USES AS ANTIBACTERIAL AGENTS | Novartis AG (CH) | 2009-04-08 | — | — | EP | disclosed |
| US-20080221142-A1 | useful in interfering with the life cycle of bacteria and in treating or preventing a bacterial infection | NOVARTIS AG (CH) | 2008-09-11 | — | — | US | disclosed |
| WO-2007142986-A2 | AMINOTHIAZOLE DERIVATIVES AND THEIR USES AS ANTIBACTERIAL AGENTS | NOVARTIS AG (CH) | 2007-12-13 | — | — | WO | disclosed |
| US-4235990-A | CRYSTALS WHICH DISPLAY INTERCALATION ACTIVITY OR CAN BE AMORPHOUS | OCCIDENTAL RESEARCH CORPORATION (US) | 1980-11-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100267757-A1 | AMINOTHIAZOLES AND THEIR USES | ABAT, AADAT, GOT2 | PPARD 284/4885AKR1B1 1156/4885ALDH1A1 353/4885 |
| US-20080221142-A1 | useful in interfering with the life cycle of bacteria and in treating or preventing a bacterial infection | LPO, PCNA, BPGM | PPARD 2012/4885AKR1B1 1430/4885ALDH1A1 1404/4885 |
| US-20140315790-A1 | AMINOTHIAZOLES AND THEIR USES | ABAT, AADAT, GOT2 | PPARD 284/4885AKR1B1 1156/4885ALDH1A1 353/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.